Thanks for sharing! The biggest takeaway for me is the timing of the catalysts. Given Euroz were running the book build for the placement, you would assume they had the inside word:
* Janssen results in March or June (vs December which is the consensus on these forums) * First revenues in March through September * Regulatory approval / FDA approval at the back end of 2021, into 2022
I would also draw your attention to the financial forecast which shows revenue growing 60% in FY22 but still off a relatively low base.
Always take broker reports with a grain of salt, but there's a few data points there to suggest that PIQ isn't going to rocket out of the gates in the next 6 weeks like a lot of us are hoping. Rather, it will be a slow and steady build but one worth sticking around for. Endometriosis and Guardia updates will be interesting, as well as any news on CVD with Promarker D, additional licensing agreements...plenty of scope to be surprised on the upside.
PIQ Price at posting:
57.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)